Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma

作者：Quande Lin, Xiyang Liu, Lu Han, Lina Liu, Baijun Fang, Quanli Gao, Yongping Song · 发表于：Bone Marrow Transplantation · 年份：2019 · DOI：10.1038/s41409-019-0674-2 · 被引用次数：24 · 研究领域：CAR-T cell therapy research、Safe Handling of Antineoplastic Drugs

Chimeric antigen receptor (CAR) T-cell targeted multiple myeloma antigens such as CD138, kappa-light chain, and B-cell maturation antigen (BCMA) as well as CD19 had been widely adopted. More and more CAR-T clinical trials for MM presented encouraging results [ 1 , 2 , 3 ]. However, current CAR-T treatment still faces the adverse reactions as cytokine release syndrome (CRS), myelosuppression, and other complications, especially, severe myelosuppression is often a fatal threat to patients. We adopted the stem cell infusion to promote hematopoietic recovery for a relapsed MM patient developing severe and persistent myelosuppression after CAR-T cell therapy.